Next Article in Journal
The Potential Effects of Probiotics and ω-3 Fatty Acids on Chronic Low-Grade Inflammation
Next Article in Special Issue
Effects of Protein Supplementation Combined with Exercise Training on Muscle Mass and Function in Older Adults with Lower-Extremity Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Trials
Previous Article in Journal
Space Flight Diet-Induced Deficiency and Response to Gravity-Free Resistive Exercise
Previous Article in Special Issue
Overfeeding and Substrate Availability, But Not Age or BMI, Alter Human Satellite Cell Function
Open AccessReview

Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps

1
Department of Geriatrics, Medical University of Bialystok, Doctoral School, Fabryczna 27, 15-471 Bialystok, Poland
2
Faculty of Medicine with the Division of Dentistry and Division of Medical Education in English, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, Poland
3
Department of Geriatrics, Medical University of Bialystok, Fabryczna 27, 15-471 Bialystok, Poland
4
Department of Geriatrics, Hospital of the Ministry of Interior and Administration in Bialystok, Fabryczna 27, 15-471 Bialystok, Poland
*
Author to whom correspondence should be addressed.
Nutrients 2020, 12(8), 2401; https://doi.org/10.3390/nu12082401
Received: 21 July 2020 / Revised: 6 August 2020 / Accepted: 8 August 2020 / Published: 11 August 2020
Sarcopenia is a geriatric syndrome with a significant impact on older patients’ quality of life, morbidity and mortality. Despite the new available criteria, its early diagnosis remains difficult, highlighting the necessity of looking for a valid muscle wasting biomarker. Myostatin, a muscle mass negative regulator, is one of the potential candidates. The aim of this work is to point out various factors affecting the potential of myostatin as a biomarker of muscle wasting. Based on the literature review, we can say that recent studies produced conflicting results and revealed a number of potential confounding factors influencing their use in sarcopenia diagnosing. These factors include physiological variables (such as age, sex and physical activity) as well as a variety of disorders (including heart failure, metabolic syndrome, kidney failure and inflammatory diseases) and differences in laboratory measurement methodology. Our conclusion is that although myostatin alone might not prove to be a feasible biomarker, it could become an important part of a recently proposed panel of muscle wasting biomarkers. However, a thorough understanding of the interrelationship of these markers, as well as establishing a valid measurement methodology for myostatin and revising current research data in the light of new criteria of sarcopenia, is needed. View Full-Text
Keywords: sarcopenia; myostatin; muscle wasting; biomarker; geriatrics; older patients sarcopenia; myostatin; muscle wasting; biomarker; geriatrics; older patients
Show Figures

Figure 1

MDPI and ACS Style

Baczek, J.; Silkiewicz, M.; Wojszel, Z.B. Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps. Nutrients 2020, 12, 2401.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop